RPLP2 and neoplasm: In this study, for the first time, we report five oncogenes (TUBA1B, SLC2A1, PGK1, CCND1, and NCAPD2) and two tumor suppressors’ genes (RPLP2, RPL37) as novel therapeutic targets in breast cancer.